BTMD Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of 28% compared to Biote's net margin of 1.08%. Biote's return on equity of -- beat Astrana Health's return on equity of 7.09%.

Biote has a consensus price target of $6.40, signalling upside risk potential of 56.05%. On the other hand Astrana Health has an analysts' consensus of $47.4444 which suggests that it could grow by 87.68%. Given that Astrana Health has higher upside potential than Biote, analysts believe Astrana Health is more attractive than Biote.

Biote has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Astrana Health has a beta of 0.842, suggesting its less volatile than the S&P 500 by 15.811%.

Biote has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biote pays 150.27% of its earnings as a dividend. Astrana Health pays out 9.35% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Biote's is not.

Biote quarterly revenues are $49M, which are smaller than Astrana Health quarterly revenues of $620.4M. Biote's net income of $13.7M is higher than Astrana Health's net income of $6.7M. Notably, Biote's price-to-earnings ratio is 6.72x while Astrana Health's PE ratio is 35.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biote is 0.72x versus 0.54x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of 28% compared to Biote's net margin of 4.49%. Biote's return on equity of -- beat Cryo-Cell International's return on equity of --.

Biote has a consensus price target of $6.40, signalling upside risk potential of 56.05%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 73.12%. Given that Cryo-Cell International has higher upside potential than Biote, analysts believe Cryo-Cell International is more attractive than Biote.

Biote has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.659, suggesting its less volatile than the S&P 500 by 34.131%.

Biote has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 13.24% to investors and pays a quarterly dividend of $0.15 per share. Biote pays 150.27% of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Biote quarterly revenues are $49M, which are larger than Cryo-Cell International quarterly revenues of $7.9M. Biote's net income of $13.7M is higher than Cryo-Cell International's net income of $355.8K. Notably, Biote's price-to-earnings ratio is 6.72x while Cryo-Cell International's PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biote is 0.72x versus 1.27x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell has a net margin of 28% compared to Biote's net margin of -2.6%. Biote's return on equity of -- beat Omnicell's return on equity of 1.73%.

Biote has a consensus price target of $6.40, signalling upside risk potential of 56.05%. On the other hand Omnicell has an analysts' consensus of $43.33 which suggests that it could grow by 55.99%. Given that Biote has higher upside potential than Omnicell, analysts believe Biote is more attractive than Omnicell.

Biote has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Omnicell has a beta of 0.761, suggesting its less volatile than the S&P 500 by 23.879%.

Biote has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biote pays 150.27% of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend.

Biote quarterly revenues are $49M, which are smaller than Omnicell quarterly revenues of $269.7M. Biote's net income of $13.7M is higher than Omnicell's net income of -$7M. Notably, Biote's price-to-earnings ratio is 6.72x while Omnicell's PE ratio is 60.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biote is 0.72x versus 1.14x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of 28% compared to Biote's net margin of -5.49%. Biote's return on equity of -- beat P3 Health Partners's return on equity of -53.56%.

Biote has a consensus price target of $6.40, signalling upside risk potential of 56.05%. On the other hand P3 Health Partners has an analysts' consensus of $8.00 which suggests that it could grow by 23.08%. Given that Biote has higher upside potential than P3 Health Partners, analysts believe Biote is more attractive than P3 Health Partners.

Biote has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Biote has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biote pays 150.27% of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

Biote quarterly revenues are $49M, which are smaller than P3 Health Partners quarterly revenues of $373.2M. Biote's net income of $13.7M is higher than P3 Health Partners's net income of -$20.5M. Notably, Biote's price-to-earnings ratio is 6.72x while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biote is 0.72x versus 0.01x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.